Key Takeaways
- PCI can reopen a coronary artery during an acute heart attack and can relieve limiting angina in selected stable disease. A visible narrowing alone does not explain what benefit an individual patient should expect.
- “One stent” is not a complete plan. Vessel, lesion length, calcification, bifurcation, chronic total occlusion, stent dimensions, imaging guidance and untreated disease all affect the procedure and its durability.
- Complex left-main or multivessel disease may require comparison with coronary bypass surgery. A Heart Team decision can be more important than immediate treatment in the catheterisation laboratory.
- After a coronary stent, antiplatelet therapy is part of the procedure—not optional aftercare. Duration and drug choice depend on whether the event was acute or stable, and on both clotting and bleeding risk.
- Before medical travel, confirm that the required antiplatelet medicines are affordable and available at home. Never stop them for dental work, surgery, bleeding concerns or travel without a coordinated clinical plan.
Content
Percutaneous coronary intervention (PCI) is a catheter-based treatment for a narrowed or blocked coronary artery. A small balloon is commonly expanded at the lesion and a mesh stent is deployed to hold the lumen open.[1] There is no chest incision, but PCI is still an invasive cardiovascular procedure with consequences that continue long after the puncture site heals.
The most important decision is not which stent brand is offered. It is whether opening this artery now is the right strategy, what clinical outcome is expected, and whether the patient can safely complete the medicines and follow-up that protect the result.
Name the clinical setting before comparing PCI offers
The same word, “stent,” can describe very different decisions:
- Acute coronary syndrome (ACS): sudden plaque disruption and clot may threaten heart muscle. PCI can be an urgent method of restoring blood flow.
- Chronic coronary disease with angina: PCI may be considered when symptoms remain unacceptable despite appropriate medicines or when anatomy and ischaemia indicate a specific benefit.
- Incidentally discovered stenosis: a narrowing found on imaging may not be the cause of symptoms and does not automatically require intervention.
- Previous PCI failure or recurrent disease: the problem may be in-stent restenosis, stent thrombosis, disease at an edge or a different vessel; each needs a different explanation.
The 2023 chronic coronary disease guideline stresses patient-centred decisions, lifestyle and preventive treatment, and advises against routine repeat anatomical or ischaemia testing when symptoms and functional status have not changed.[2] PCI treats a particular flow-limiting problem; it does not remove the underlying tendency to atherosclerosis throughout the coronary circulation.
Ask the cardiologist to complete one sentence: “For this patient, PCI is intended to .” Possible answers include rescue threatened heart muscle, reduce angina, improve exercise capacity, or address a high-risk anatomical situation. If the answer is simply “because it is 70%,” the reasoning is incomplete.
Decide whether PCI, surgery or medical therapy is the better route
Coronary anatomy is only one part of revascularisation. Diabetes, heart-pumping function, kidney disease, frailty, bleeding risk, prior bypass grafts, other planned surgery and patient priorities matter. For significant left-main disease, complex multivessel disease or an unclear best strategy, guidelines support multidisciplinary Heart Team discussion.[3]
Before an elective procedure, ask:
- What happens if treatment continues with medicines alone?
- What benefit is expected from PCI, and over what time frame?
- Is coronary bypass surgery a reasonable alternative?
- Is every important lesion being treated now, or is treatment intentionally staged?
- What finding would make the operator stop and seek another opinion?
A patient should have time to consider these questions before sedation. When PCI is proposed immediately after diagnostic angiography, consent should be patient-specific and obtained early enough for meaningful questions, not reduced to a signature once the catheter is already in place.[4]
The lesion determines the tools
A procedural estimate should describe the coronary problem, not merely count stents. Ask whether the target is:
- short and straightforward or long and diffuse;
- heavily calcified and likely to need plaque modification;
- at a bifurcation involving an important side branch;
- a chronic total occlusion;
- in the left main, a small vessel, an old stent or a bypass graft; or
- accompanied by other lesions whose functional importance is uncertain.
Pressure-wire measurements such as FFR or iFR can help determine whether selected intermediate lesions restrict flow. Intravascular ultrasound (IVUS) or optical coherence tomography (OCT) can examine vessel size, plaque, calcium, stent expansion and edge problems from inside the artery. The 2025 ACS guideline gives intravascular imaging a strong role in guiding PCI, especially where optimising the result matters.[5]
These technologies do not guarantee success, and not every simple lesion requires every device. The useful question is: “What uncertainty will this tool resolve in my case?” The written estimate should separate guidewires, balloons, stents, imaging or physiology catheters, calcium-modification devices, contrast, professional fees and possible additional-night costs.
What the PCI procedure involves
PCI is performed in a catheterisation laboratory with continuous ECG, blood-pressure and oxygen monitoring. Local anaesthetic is used at the wrist or groin; many patients remain awake with light sedation. Through an arterial sheath, the operator advances a guiding catheter and a fine wire across the lesion. A balloon prepares or expands the narrowed segment, and a stent mounted on a balloon is opened against the artery wall. Additional balloon inflation may be used to optimise the result.
Radial access at the wrist is guideline-preferred for PCI in ACS and stable ischaemic disease when appropriate because it reduces bleeding and vascular complications compared with femoral access.[3] A groin approach may still be chosen for anatomy, larger equipment or circulatory support. The choice should be explained, not marketed.
During balloon inflation, blood flow can be briefly reduced and the patient may feel chest pressure. New pain, breathing difficulty, nausea, itching or neurological symptoms should be reported immediately. Staff may use anticoagulant and antiplatelet medicines during the procedure. Contrast volume, radiation exposure and procedure time often rise with lesion complexity.
A drug-eluting stent is an implant, not a cure
Most contemporary coronary stents release medicine that reduces tissue overgrowth inside the stent.[1] The implant remains in the artery. A good procedure record should identify the manufacturer, model, diameter, length, lot or device identifiers where available, exact vessel segment, deployment pressure, post-dilation and final flow. It should also list residual disease that was deliberately left untreated.
Early hazards include bleeding, access-vessel injury, contrast reaction or kidney injury, coronary dissection or perforation, side-branch loss, arrhythmia, heart attack, stroke and very rarely death. Later concerns include restenosis, stent thrombosis and progression elsewhere. Risk varies greatly between an uncomplicated elective single-vessel PCI and emergency treatment in shock; a generic percentage is not a substitute for an individual risk conversation.
China's current clinical-application standard for cardiovascular intervention requires suitable institutions, trained personnel, equipment, quality systems and emergency capability.[6] For a complex elective PCI, ask about the operator's experience with that lesion type, surgical or transfer backup, intensive-care support and how complications are audited.
Antiplatelet treatment protects the stent
A stent creates a surface on which a dangerous clot can form, especially before healing is established. Dual antiplatelet therapy (DAPT) usually combines aspirin with a P2Y12 inhibitor such as clopidogrel, ticagrelor or prasugrel.[7]
There is no single duration for everyone. The 2025 ACS guideline recommends at least 12 months after discharge for many ACS patients who do not have high bleeding risk, while offering alternative strategies for higher bleeding risk.[5] In selected stable-disease patients, contemporary guidance allows shorter DAPT and transition to single-antiplatelet treatment after balancing ischaemic and bleeding risks.[2][3]
Before PCI, the discharge plan should already answer:
- exact generic names, doses and dosing times;
- intended duration of both-drug and one-drug phases;
- what to do after a missed or vomited dose;
- relevant interactions, including non-prescription anti-inflammatory drugs;
- which clinician can approve any interruption;
- what bleeding requires urgent care; and
- whether the same formulation is reliably obtainable after return home.
If the patient also needs long-term anticoagulation for atrial fibrillation, a mechanical valve, venous thrombosis or another reason, the combined regimen requires specialist design. “Take all three blood thinners” without dates is unsafe.
Do not stop treatment because bruising appears, the prescription runs out, a dentist requests it, or another surgeon prefers it. The cardiologist who understands the stent timing and thrombosis risk should coordinate any change with the clinician managing the procedure or bleeding.[7]
Recovery is also secondary prevention
After PCI, monitoring focuses on recurrent chest symptoms, rhythm, circulation beyond the puncture, bleeding and kidney or heart status when relevant. Discharge may be same-day in selected elective cases or longer after ACS, complex intervention or complications.
The stent fixes one segment; long-term risk reduction still depends on cholesterol-lowering treatment, blood-pressure and diabetes management, smoking cessation, physical activity, nutrition and cardiac rehabilitation where indicated.[2] Ask for a rehabilitation referral that can be used at home and a staged return-to-activity plan rather than a vague instruction to “rest.”
Seek urgent local care for new or persistent chest pressure, marked breathlessness, fainting, stroke symptoms, uncontrolled puncture-site bleeding, a rapidly expanding swelling or a cold/pale/numb hand or leg. Never wait for an international reply when a possible heart attack or major bleed is occurring.
Build a cross-border stent record
Before leaving the treating hospital, obtain:
- diagnostic angiography and PCI reports plus the full image study;
- stent and other device identifiers, sizes and implanted locations;
- IVUS/OCT or FFR/iFR findings if used;
- contrast volume, access route and any complication;
- baseline and discharge ECG, echocardiogram and relevant laboratory results;
- exact discharge medicines and stop/review dates;
- residual coronary disease and staged-procedure plan;
- fitness-to-fly advice and activity limits; and
- named contacts for procedural and medication questions.
Send these records to the home cardiologist before travel when possible. A stent card is useful, but it does not replace the procedure report, images and medication plan.
Medical disclaimer: This article provides general education, not a recommendation for PCI or a specific antiplatelet regimen. Possible heart-attack symptoms, major bleeding or limb-circulation changes require immediate local medical care.
FAQ
Does a 70% coronary narrowing always need a stent?
No. The decision depends on symptoms, acute versus chronic presentation, ischaemia, vessel and lesion anatomy, medical therapy, heart function and alternatives.[2][3] A percentage estimated from one image is only part of the assessment.
What is the difference between balloon angioplasty and a stent?
The balloon temporarily expands the narrowed segment. A stent is a mesh implant opened against the vessel wall to help keep the lumen open; modern stents commonly release medicine to reduce tissue regrowth.[1]
How long must dual antiplatelet therapy continue?
Duration varies. Many lower-bleeding-risk ACS patients are advised to continue DAPT for at least 12 months, while selected higher-bleeding-risk or stable-disease patients may use shorter strategies under specialist guidance.[2][5] The discharge record should give exact drugs and dates.
Can I pause antiplatelet medicine for dental work or surgery?
Not without coordinated advice. Stopping too early can allow a clot to form in the stent.[7] The interventional cardiologist and the clinician planning the dental or surgical procedure should balance thrombosis and bleeding risk and document the plan.
What should I know about an untreated narrowing after PCI?
Ask where it is, how severe it is, whether physiology was assessed, why it was left untreated, and what symptoms or test results would trigger review. The report should distinguish deliberately deferred disease from a lesion planned for staged PCI or bypass discussion.
Sources
- American Heart Association — What Is a Stent?
- American Heart Association — 2023 Guideline for the Management of Patients With Chronic Coronary Disease: Top Things to Know
- American College of Cardiology — 2021 ACC/AHA/SCAI Coronary Revascularization Guideline: Key Perspectives
- Society for Cardiovascular Angiography and Interventions — Ad Hoc PCI Consensus Statement
- American College of Cardiology — 2025 Acute Coronary Syndromes Guideline
- 国家卫生健康委员会 — 心血管疾病介入诊疗技术临床应用管理规范（2019年版）
- American Heart Association — Aspirin and Dual Antiplatelet Therapy
Image Review
- Decision: Approved and retained as hero-reviewed.png.
- Editorial note: The image accurately presents a simplified sequence of balloon dilation and stent expansion. It does not imply that every coronary narrowing requires a stent.